RxDoctor Payments Data

Jose Reyes Pena, MD

Cardiovascular Disease · Guaynabo, PRNPI 1720071483

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Medtronic at 58.4% of the total. Reporting peaked in 2019 at $2,893 and has fallen 75.7% since, to $703 in 2025.

$11,269in general payments, 2019–2025

Across 190 payments — averaging $59.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Abbott$2K
  • Johnson & Johnson$761
  • AstraZeneca$524
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$429
  • PBG Puerto Rico LLC$406
  • plus $613 from 7 others

What the payments were for

  • Food & beverage$11,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic66$6,580
Abbott19$1,957
Johnson & Johnson29$761
AstraZeneca21$524
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)17$429
PBG Puerto Rico LLC19$406
Merck3$204
Amgen10$198
Actelion Pharmaceuticals US, Inc.1$95
Bayer Puerto Rico Inc.2$51
Boston Scientific1$23
Boehringer Ingelheim1$21
Pfizer Pharmaceuticals LLC1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,269 in reported general payments places this provider in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$30,907
Medicare patients
91
Services billed
356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$257,421
XareltoRivaroxaban118$76,339
FarxigaDapagliflozin Propanediol67$42,805
BrilintaTicagrelor57$26,818
Repatha SureclickEvolocumab15$8,916
Atorvastatin Calcium771$6,166
Amiodarone Hcl73$6,007
SynthroidLevothyroxine Sodium73$4,726
Metoprolol Succinate390$4,225
Verapamil ErVerapamil Hcl185$4,122
Losartan Potassium446$3,935
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide118$3,130
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide247$2,983
Rosuvastatin Calcium273$2,956
Enalapril Maleate149$2,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$761$76,339118 claims
AstraZenecaFarxiga, Brilinta$524$69,623124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →